Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy

Purpose: We sought to test the hypothesis that the presence of telomerase activity in peritoneal washings of patients treated for ovarian carcinoma is a sensitive and specific indicator of the presence of residual disease. We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma. Experimental Design: Peritoneal washings were obtained from 100 consecutive patients undergoing a second-look procedure after treatment for ovarian carcinoma (cases) and from 100 patients undergoing surgery for benign gynecological conditions (controls). The washings were assayed for telomerase activity using the telomerase repeat amplification protocol. The results were compared to the histological and cytological findings. Results: Among our 100 cases, 82 (82%) had either positive second-look procedures or expressed telomerase in their peritoneal washings. Fifty-three (53%) had positive second-look procedures, whereas 66 (66%) tested positive for telomerase. Twenty-nine of the 47 patients (62%) with negative second-look procedures tested positive for telomerase. Of the 53 patients with positive second-look procedures, 37 (70%) tested positive for telomerase. None of the 100 controls (0%) expressed telomerase in their peritoneal washings. Conclusions: Telomerase activity in peritoneal washings of patients treated for ovarian carcinoma and undergoing a second-look procedure may provide a means of increasing the sensitivity of such procedures for the detection of residual disease while maintaining a high level of specificity.

[1]  M. Hendrix,et al.  p53 Null Mutations are Associated with a Telomerase Negative Phenotype in Ovarian Carcinoma , 2002, Cancer biology & therapy.

[2]  P. Sevelda,et al.  Impact of second look laparotomy and secondary cytoreductive surgery at second‐look laparotomy in ovarian cancer patients , 2001, Acta obstetricia et gynecologica Scandinavica.

[3]  S. Martin,et al.  Detection of ovarian cancer cells: comparison of a telomerase assay and cytologic examination. , 1998, Journal of the National Cancer Institute.

[4]  G. Strauss,et al.  The role of second-look laparotomy in the long-term survival in ovarian cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  J. Felix,et al.  Telomerase activity in benign and malignant epithelial ovarian tumors. , 1997, Journal of the National Cancer Institute.

[6]  P. Conti,et al.  Second-look laparotomy for stage III epithelial ovarian cancer: rationale and current issues. , 1995, Cancer treatment reviews.

[7]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[8]  W. Cliby,et al.  Second-look surgery in the management of epithelial ovarian carcinoma. , 1994, Gynecologic oncology.

[9]  J. Berek,et al.  The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. , 1994, American journal of obstetrics and gynecology.

[10]  C. Greider.  Mammalian telomere dynamics: healing, fragmentation shortening and stabilization. , 1994, Current opinion in genetics & development.

[11]  C B Harley,et al.  Telomere length predicts replicative capacity of human fibroblasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  N. Teng,et al.  Critical reassessment of second‐look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer , 1992, Cancer.

[13]  P. Saigo,et al.  Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. , 1991, Gynecologic oncology.

[14]  K. Olesen,et al.  Correlation of abdominal ultrasound and computed tomography scans with second‐ or third‐look laparotomy in patients with ovarian carcinoma , 1991, Gynecologic oncology.

[15]  J. Cain,et al.  The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer. , 1991, Gynecologic oncology.

[16]  R. Mortel,et al.  Second‐look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group study) , 1990, Gynecologic oncology.

[17]  C. Harley,et al.  Telomeres shorten during ageing of human fibroblasts , 1990, Nature.

[18]  N. Weiss,et al.  Second thoughts about second-look laparotomy in advanced ovarian cancer. , 1990, The New England journal of medicine.

[19]  J. Cain,et al.  Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. , 1988, American journal of obstetrics and gynecology.

[20]  S. Cha,et al.  Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. , 1988, Gynecologic oncology.

[21]  R. Bast,et al.  CA 125 serum levels correlated with second-look operations among ovarian cancer patients. , 1986, Obstetrics and gynecology.

[22]  W. Creasman,et al.  Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission. Correlation with surgical-pathologic findings. , 1986, JAMA.

[23]  G. Malkasian,et al.  Second-look laparotomy in ovarian cancer: evaluation of pathologic variables. , 1985, American journal of obstetrics and gynecology.

[24]  R. Bast,et al.  Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. , 1985, American journal of obstetrics and gynecology.

[25]  N. Sneige,et al.  Prognosis of surgically determined complete responders in advanced ovarian cancer , 1985, Cancer.

[26]  N. Sneige,et al.  Microscopic disease at second‐look laparotomy in advanced ovarian cancer , 1985, Cancer.

[27]  N. Hacker,et al.  Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status. , 1984, Obstetrics and gynecology.

[28]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[29]  R. Elashoff,et al.  Survival of Patients Following Secondary Cytoreductive Surgery in Ovarian Cancer , 1983, Obstetrics and gynecology.

[30]  A M Olovnikov,et al.  A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. , 1973, Journal of theoretical biology.

[31]  G. W. Snedecor.  STATISTICAL METHODS , 1967 .

[32]  T C Randall,et al.  Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. , 1999, Obstetrics and gynecology.

[33]  F. Parazzini,et al.  Survival of women with advanced ovarian cancer and complete pathologic response at second‐look laparotomy , 1996, Cancer.

[34]  K. Hatch,et al.  Second-look laparotomy and salvage therapy: a research modality only? , 1992, Gynecologic oncology.

[35]  G. Sutton,et al.  A comparison of findings at second-look laparotomy with preoperative computed tomography in patients with ovarian cancer. , 1988, Gynecologic oncology.